COURT BLOCKS FDA REGULATION OF LABORATORY DEVELOPED TESTS
April 2, 2025
The recent federal court decision striking down the FDA’s attempted regulation of laboratory developed tests represents a significant development for diagnostic laboratory innovation. This ruling removes a significant cost, regulatory burden, and barriers to the development of novel clinical tests for the patient community.
The Court’s Decision on FDA Regulation
On March 31, Judge Sean Jordan of the Eastern District of Texas vacated the FDA’s Final Rule on Laboratory Developed Tests in its entirety. The court determined that the FDA exceeded its statutory authority in attempting to regulate LDTs as medical devices. This decision halts the May 6th compliance deadline that would have required laboratories to implement aspects of FDA’s medical device quality system regulations.
The ruling was based on several key findings:
- The FDA’s attempt to expand jurisdiction to cover laboratory testing services as medical “devices” under the FDCA is not supported by statute
- The opinion holds that FDA’s device authorities are limited to “tangible, physical products” but that LDT services are “professional medical services that are qualitatively and categorically distinct.”
- Congress had specifically addressed laboratory regulation through CLIA’s framework
- The proposed regulation would have created duplicative oversight, as laboratories are already regulated under CLIA
- Authority over laboratory operations was deliberately vested in CMS, not FDA
Having concluded that the rule exceeds FDA’s authority and is unlawful, the district court vacated the rule and remanded it to FDA for further consideration.
The Long History of CLIA and FDA Regulatory Frameworks
The regulatory framework for laboratory testing in the United States has evolved through several distinct phases. Since the mid-1970s, the FDA has asserted regulatory authority over tests performed in clinical laboratories under the Medical Device Regulation Act, while generally exercising “enforcement discretion” for most LDTs.
Concurrently, the Clinical Laboratory Improvement Amendments (CLIA) of 1988 established comprehensive federal standards for laboratory testing. CLIA requires laboratories to obtain appropriate certification based on test complexity before accepting human specimens, ensuring quality and reliability through analytical validation requirements.
The regulatory approach to LDTs has followed an inconsistent path:
- 1992: FDA issued a draft Compliance Policy Guide claiming authority over LDTs but did not finalize
- 2010-2016: The FDA proposed more stringent LDT regulation but did not implement formal rules
- 2020: HHS explicitly revoked FDA’s guidance on LDT regulation during the first Trump administration
- 2024: FDA issued its Final Rule in May, attempting to phase out “enforcement discretion” and regulate LDTs as medical devices
This regulatory uncertainty has created significant compliance challenges for laboratories developing innovative tests, particularly those serving patients with rare diseases or in emerging therapeutic areas.
Benefits for Laboratory Innovation and Patient Access
The court’s ruling has significant implications for laboratory medicine innovation and patient care:
- Regulatory Efficiency: Maintains the established CLIA framework without adding redundant FDA requirements
- Resource Optimization: Allows laboratories to direct resources toward test development rather than compliance with multiple regulatory schemes
- Laboratory Innovation Preservation: Protects the development pathway for novel tests, particularly those serving patients with rare conditions
- Continued Access: Ensures laboratories can continue offering specialized diagnostics without additional regulatory burden
- Cost Containment: Prevents potential increases in healthcare costs that would have resulted from more complex regulatory requirements
Martin Price, Executive Chairman & CEO of HealthTrackRx, noted that the decision “protected patient access to vital diagnostic testing, ensured continued innovation in laboratory medicine, and prevented unnecessary regulatory burdens that would have resulted in increased healthcare costs and delayed critical diagnoses.”
Laboratory-developed tests have driven critical diagnostic advances in numerous clinical areas including oncology, infectious disease, and rare genetic disorders. The court’s decision will help maintain the innovation ecosystem necessary for continued development of cutting-edge diagnostics.
Regulatory Outlook: Administration Response and Congressional Action
Although this decision is a significant development in the saga of attempting to regulate LDTs—and a resounding victory for the laboratories—there is likely more to follow.
Following the court’s decision, several regulatory pathways are possible:
Department of Justice Response Given the current administration’s previous actions regarding LDT regulation, experts anticipate that the DOJ is unlikely to appeal the decision. During President Trump’s first term, HHS revoked FDA’s guidance document claiming authority to regulate LDTs as devices, indicating a consistent regulatory philosophy.
Congressional Consideration The court’s decisive ruling diminishes the likelihood that Congress, particularly the Republican-controlled House, will prioritize reviving the bipartisan VALID Act. This legislation, which would have explicitly granted FDA authority to regulate LDTs, failed to pass during the Biden administration despite multiple attempts.
Administrative Approach While the DOJ and administration in general do not wish a single judge to impact national policies, the Trump administration not likely to take action as their position on laboratory testing aligns with an emphasis on innovation and reduced regulatory burden.
Industry Response Clinical laboratories and industry organizations have expressed strong support for the court’s decision. Laboratory stakeholders are expected to continue working with CMS to ensure that CLIA requirements effectively address quality and safety considerations while supporting innovation.
Implications for Laboratory Medicine
The court’s ruling represents a significant recalibration of the regulatory landscape for diagnostic testing. By maintaining the established CLIA framework while preventing FDA from imposing additional requirements, the decision removes for the moment regulatory uncertainty that laboratories have navigated for years.
This outcome should enable laboratories to focus resources on developing innovative diagnostic solutions rather than navigating complex and potentially duplicative regulatory requirements. For patients, this means continued access to cutting-edge diagnostic tests that can detect diseases earlier, guide treatment decisions more precisely, and potentially improve healthcare outcomes.
As the laboratory industry proceeds under the established CLIA framework, stakeholders will need to maintain focus on quality, reliability, and clinical validation through scientifically rigorous processes. Continued industry engagement with CMS to strengthen and modernize CLIA/CAP requirements will be essential to ensure that the regulatory framework evolves alongside technological advances in laboratory medicine.
